Biogen (BIIB) PT Raised to $458 at Truist Securities
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $210.65 +0.85%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 9
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 9
Join SI Premium – FREE
Truist Securities analyst Robyn Karnauskas raised the price target on Biogen (NASDAQ: BIIB) to $458.00 (from $443.00) while maintaining a Buy rating.
You May Also Be Interested In
- Wolfe Research Upgrades Biogen (BIIB) to Outperform
- Cellebrite (CLBT) PT Lowered to $15 at TD Cowen
- STAAR Surgical (STAA) PT Lowered to $28 at Jefferies
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
